Literature DB >> 11186149

A humanized anti--4-1BB monoclonal antibody suppresses antigen-induced humoral immune response in nonhuman primates.

H J Hong1, J W Lee, S S Park, Y J Kang, S Y Chang, K M Kim, J O Kim, K K Murthy, J S Payne, S K Yoon, M J Park, I C Kim, J G Kim, C Y Kang.   

Abstract

The interaction of 4-1BB and its ligand plays an important role in the regulation of T-cell-mediated immune responses. In this study, the authors examined the effect of a humanized anti--4-1BB monoclonal antibody (H4B4) on ovalbumin-induced immune responses in baboons. Previously, a mouse monoclonal antibody, 4B4 against the human 4-1BB molecule, was generated and characterized. Based on this antibody, a humanized version of 4B4 monoclonal antibody was constructed and the resultant antibody, H4B4, showed full recovery of the binding activity of the original antibody 4B4: a 1.5-fold increase in affinity for 4-1BB. In addition, H4B4 mediated antibody-dependent cellular cytotoxicity of activated human peripheral blood T cells and CEM cells in a dose-dependent manner. Weekly administration of H4B4 at doses of 1 or 4 mg/kg could suppress immunoglobulin G production against ovalbumin. This was not a result of the overall immune suppression, because the numbers of B and T cells and the total immunoglobulin G production were not altered during treatment with H4B4. These findings suggest that treatment with H4B4 may be a valid therapeutic approach to control unwanted immune responses in persons with autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11186149     DOI: 10.1097/00002371-200011000-00002

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  11 in total

Review 1.  The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy.

Authors:  Amy E Moran; Magdalena Kovacsovics-Bankowski; Andrew D Weinberg
Journal:  Curr Opin Immunol       Date:  2013-02-14       Impact factor: 7.486

Review 2.  CD137 and CD137L signals are main drivers of type 1, cell-mediated immune responses.

Authors:  Bhushan Dharmadhikari; Meihui Wu; Nur Sharalyn Abdullah; Sakthi Rajendran; Nur Diana Ishak; Emily Nickles; Zulkarnain Harfuddin; Herbert Schwarz
Journal:  Oncoimmunology       Date:  2015-11-11       Impact factor: 8.110

Review 3.  Dual immunoregulatory pathways of 4-1BB signaling.

Authors:  Dass S Vinay; Kiweon Cha; Byoung S Kwon
Journal:  J Mol Med (Berl)       Date:  2006-08-05       Impact factor: 4.599

Review 4.  Therapeutic vaccination with tumor cells that engage CD137.

Authors:  Karl Erik Hellstrom; Ingegerd Hellstrom
Journal:  J Mol Med (Berl)       Date:  2003-02-08       Impact factor: 4.599

Review 5.  Clinical targeting of the TNF and TNFR superfamilies.

Authors:  Michael Croft; Chris A Benedict; Carl F Ware
Journal:  Nat Rev Drug Discov       Date:  2013-01-21       Impact factor: 84.694

6.  CD137 costimulatory T cell receptor engagement reverses acute disease in lupus-prone NZB x NZW F1 mice.

Authors:  Juergen Foell; Simona Strahotin; Shawn P O'Neil; Megan M McCausland; Carolyn Suwyn; Michael Haber; Praveen N Chander; Abhijit S Bapat; Xiao-Jie Yan; Nicholas Chiorazzi; Michael K Hoffmann; Robert S Mittler
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

7.  Agonistic Anti-CD137 Monoclonal Antibody Treatment Induces CD11bGr-1 Myeloid-derived Suppressor Cells.

Authors:  Jung-Mi Lee; Jeong-Hwan Seo; Yeon-Jeong Kim; Yun-Sun Kim; Hyun-Jeong Ko; Chang-Yuil Kang
Journal:  Immune Netw       Date:  2010-06-30       Impact factor: 6.303

Review 8.  Liver macrophages and inflammation in physiology and physiopathology of non-alcoholic fatty liver disease.

Authors:  Ronan Thibaut; Matthew C Gage; Inès Pineda-Torra; Gwladys Chabrier; Nicolas Venteclef; Fawaz Alzaid
Journal:  FEBS J       Date:  2021-05-02       Impact factor: 5.622

Review 9.  Role of TRAFs in Signaling Pathways Controlling T Follicular Helper Cell Differentiation and T Cell-Dependent Antibody Responses.

Authors:  Christophe Pedros; Amnon Altman; Kok-Fai Kong
Journal:  Front Immunol       Date:  2018-10-22       Impact factor: 7.561

Review 10.  Costimulation-based immunotherapy for head and neck cancer.

Authors:  Scott E Strome; Lieping Chen
Journal:  Curr Treat Options Oncol       Date:  2004-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.